

In the claims:

Please amend the claims as follows:

1-15. (Cancelled).

16-42. (Withdrawn).

43. (Currently Amended) A method for reducing immune-mediated damage to cells, tissues or organs associated with graft versus host disease, the method comprising ~~contacting a cell, tissue or organ with~~ administering to a transplant patient an immunoprotective amount of a polypeptide consisting of the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

44. (Currently Amended) A method for reducing immune-mediated damage to cells, tissues or organs associated with graft versus host disease, the method comprising ~~contacting a cell, tissue or organ with~~ administering to a transplant patient an immunoprotective amount of a polypeptide comprising the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3)

45. (Currently Amended) A method for reducing immune-mediated damage to cells, tissues or organs associated with graft versus host disease, the method comprising ~~contacting a cell, tissue or organ with~~ administering to a transplant patient an immunoprotective amount of a polypeptide consisting essentially of the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment of SEQ ID NO:6 comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

46. (Currently Amended) A method for reducing immune-mediated damage to cells, tissues or organs associated with graft versus host disease, the method comprising ~~contacting a~~

~~cell, tissue or organ with~~ administering to a transplant patient an immunoprotective amount of a polypeptide comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

F1 cont
47. (Currently Amended) A method for reducing immune-mediated damage to cells, tissues or organs associated with graft versus host disease, the method comprising ~~contacting a cell, tissue or organ with~~ administering to a transplant patient immunoprotective amount of a polypeptide consisting essentially of the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

48-56. (Cancelled).

F2
57. (Currently Amended) The method of any one of claims 43-47 further comprising administering to the transplant patient ~~contacting the cells, tissues or organs with~~ a composition comprising brefeldin A.

58-59. (Cancelled)

F3
60. (New) The method of any of claims 43-47 and 57 wherein the transplant patient is a bone marrow transplant patient.
